IDEXX Laboratories, Inc. (IDXX)
IDEXX Stock Up on Q2 Earnings & Revenue Beat, Margins Expand
IDXX posts double-digit Q2 revenue growth, beats EPS estimates and lifts the full-year outlook as margins rise sharply.
Idexx (IDXX) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for Idexx (IDXX) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
IDEXX Laboratories Stock Jumps as Pet Health Care Firm Lifts Full-Year Outlook
Shares of IDEXX Laboratories (IDXX) soared more than 10% in premarket trading Monday after the pet health care company reported better-than-expected second-quarter results and raised its 2025 profit and revenue forecasts.
Idexx Laboratories (IDXX) Tops Q2 Earnings and Revenue Estimates
Idexx Laboratories (IDXX) came out with quarterly earnings of $3.63 per share, beating the Zacks Consensus Estimate of $3.31 per share. This compares to earnings of $2.44 per share a year ago.
Idexx (IDXX) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates
Beyond analysts' top-and-bottom-line estimates for Idexx (IDXX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2025.
Idexx Laboratories (IDXX) Earnings Expected to Grow: Should You Buy?
Idexx (IDXX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IDEXX to Release Q2 Earnings: What's in Store for the Stock?
IDXX eyes a Q2 earnings jump with CAG growth, global pricing gains, and momentum in water and software segments.
IDEXX Laboratories: A Business With Strong Fundamentals
I rate IDEXX Laboratories a buy, driven by a lasting surge in pet ownership and IDXX's leadership in veterinary diagnostics. New platforms like inVue Dx and Cancer Dx provide additional growth drivers, with strong early adoption and potential for margin expansion. IDXX's recurring revenue model, robust retention, and expanding high-margin consumables base support sustained revenue and earnings growth.
Idexx (IDXX) is an Incredible Growth Stock: 3 Reasons Why
Idexx (IDXX) could produce exceptional returns because of its solid growth attributes.
Will Idexx (IDXX) Beat Estimates Again in Its Next Earnings Report?
Idexx (IDXX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
IDEXX Laboratories: Growth Remains Despite Weak Clinical Visits
IDEXX Laboratories, Inc. delivered strong Q1 FY25 results with 4.7% organic revenue and 7% adjusted EPS growth, despite weak US clinical visits. I see catalysts ahead: potential U.S. tax cuts, normalization of consumer spending, and robust pricing power supporting profit growth. Management guides for 6%-9% organic revenue and 8%-12% adjusted EPS growth in FY25; I model 8.2% revenue growth and margin expansion.
Is IDEXX Laboratories (IDXX) Outperforming Other Medical Stocks This Year?
Here is how Idexx Laboratories (IDXX) and AngioDynamics (ANGO) have performed compared to their sector so far this year.
